Pam R Taub Selected Research

Catechin (Z 7300)

1/2018	A pilot study on clinical pharmacokinetics and preclinical pharmacodynamics of (+)-epicatechin on cardiometabolic endpoints.
9/2016	Beneficial effects of dark chocolate on exercise capacity in sedentary subjects: underlying mechanisms. A double blind, randomized, placebo controlled trial.
1/2014	Effects of (-)-epicatechin on molecular modulators of skeletal muscle growth and differentiation.
10/2013	(-)-Epicatechin rich cocoa mediated modulation of oxidative stress regulators in skeletal muscle of heart failure and type 2 diabetes patients.
10/2013	Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: restorative effects of (-)-epicatechin-rich cocoa.
2/2012	Alterations in skeletal muscle indicators of mitochondrial structure and biogenesis in patients with type 2 diabetes and heart failure: effects of epicatechin rich cocoa.
9/2011	(-)-Epicatechin enhances fatigue resistance and oxidative capacity in mouse muscle.
6/2010	Effects of (-)-epicatechin on myocardial infarct size and left ventricular remodeling after permanent coronary occlusion.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pam R Taub Research Topics

Disease

15	Heart Failure 10/2021 - 04/2009
6	Cardiovascular Diseases (Cardiovascular Disease) 10/2021 - 02/2013
6	Type 2 Diabetes Mellitus (MODY) 12/2019 - 02/2012
5	Body Weight (Weight, Body) 10/2021 - 06/2010
4	COVID-19 01/2022 - 03/2020
4	Infarction (Infarctions) 01/2020 - 06/2010
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2020 - 01/2013
3	Inflammation (Inflammations) 01/2021 - 12/2015
2	Hypertension (High Blood Pressure) 01/2022 - 02/2013
2	Coronary Artery Disease (Coronary Atherosclerosis) 10/2021 - 01/2021
2	Obesity 01/2021 - 01/2018
2	Ulcerative Colitis 01/2021 - 01/2020
2	Heart Diseases (Heart Disease) 12/2020 - 05/2012
2	Insulin Resistance 01/2019 - 01/2018
2	Neoplasms (Cancer) 01/2018 - 04/2012
2	Myocardial Infarction 01/2018 - 06/2010
2	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2013 - 04/2012
1	Myocarditis (Carditis) 01/2022
1	Cognitive Dysfunction 01/2022
1	Post-Acute COVID-19 Syndrome 01/2022
1	Hypoglycemia (Reactive Hypoglycemia) 01/2022
1	Prediabetic State (Prediabetes) 01/2022
1	Non-alcoholic Fatty Liver Disease 01/2022
1	Overweight 10/2021
1	Dyslipidemias (Dyslipidemia) 01/2021
1	Abdominal Obesity 01/2021
1	Supraventricular Tachycardia 01/2021
1	Bradycardia 01/2021
1	Hyperlipidemias (Hyperlipidemia) 01/2021
1	Hypotension (Low Blood Pressure) 01/2021
1	Rheumatoid Arthritis 01/2021
1	Postural Orthostatic Tachycardia Syndrome 01/2021
1	Cardiomyopathies (Cardiomyopathy) 01/2021
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2021
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2021
1	Sinus Tachycardia 01/2021
1	Atherosclerosis 01/2021
1	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 12/2020
1	Hypercholesterolemia 12/2020
1	Diabetes Mellitus 01/2019
1	Weight Gain 01/2018
1	Injection Site Reaction 01/2018
1	Left Ventricular Dysfunction 01/2018
1	Body Weight Changes 04/2016
1	Metabolic Diseases (Metabolic Disease) 12/2015
1	Mitochondrial Diseases (Mitochondrial Disease) 12/2015
1	Hypoxia (Hypoxemia) 04/2014
1	Respiratory Tract Infections (Respiratory Tract Infection) 04/2014
1	Tachypnea 04/2014
1	Sarcopenia 01/2014
1	Chronic Disease (Chronic Diseases) 05/2012
1	Acute Kidney Injury (Acute Renal Failure) 05/2012

Drug/Important Bio-Agent (IBA)

9	Biomarkers (Surrogate Marker)IBA 01/2021 - 07/2010
8	Catechin (Z 7300)IBA 01/2018 - 06/2010
7	LipidsIBA 01/2022 - 12/2015
4	Brain Natriuretic Peptide (Natrecor)FDA Link 04/2016 - 08/2011
3	oxidized low density lipoproteinIBA 10/2021 - 02/2013
3	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2018
3	C-Reactive ProteinIBA 01/2020 - 02/2013
3	Natriuretic PeptidesIBA 05/2012 - 07/2010
2	LDL CholesterolIBA 10/2021 - 01/2021
2	CholesterolIBA 01/2021 - 01/2018
2	tofacitinibIBA 01/2021 - 01/2020
2	IvabradineIBA 01/2021 - 01/2021
2	Pharmaceutical PreparationsIBA 12/2020 - 01/2018
2	Proprotein Convertase 9IBA 12/2020 - 01/2018
2	Lipocalin-2IBA 05/2012 - 07/2010
2	CreatinineIBA 05/2012 - 04/2012
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2022
1	SolutionsIBA 01/2022
1	Blood Glucose (Blood Sugar)IBA 01/2021
1	lipoprotein cholesterolIBA 01/2021
1	Metoprolol (Toprol-XL)FDA LinkGeneric 01/2021
1	InflammasomesIBA 01/2021
1	CytokinesIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 12/2020
1	succinic acid mono- (4- (18- (4- (3- carboxypropionyloxy)- 2,6,6- trimethyl- 3- oxocyclohex- 1- enyl)- 3,7,12,16- tetramethyloctadeca- 1,3,5,7,9,11,13,15,17- nonaenyl)- 3,5,5- trimethyl- 2- oxocyclohex- 3- enyl) esterIBA 12/2020
1	Antihypertensive Agents (Antihypertensives)IBA 01/2020
1	Janus Kinase InhibitorsIBA 01/2020
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020
1	SodiumIBA 12/2019
1	SymportersIBA 12/2019
1	Peptide Hydrolases (Proteases)FDA Link 01/2019
1	Insulin ReceptorIBA 01/2019
1	Triglycerides (Triacylglycerol)IBA 01/2018
1	Lipoproteins (Lipoprotein)IBA 01/2018
1	alirocumabIBA 01/2018
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2015
1	ProcalcitoninIBA 04/2014
1	AdiponectinIBA 02/2013
1	LDL Lipoproteins (beta Lipoproteins)IBA 02/2013
1	Arginine Vasopressin (Argipressin)IBA 01/2013
1	Cystatin CIBA 05/2012

Therapy/Procedure

6	Therapeutics 01/2022 - 07/2010
3	Cardiac Rehabilitation 11/2021 - 01/2021
2	Drug Therapy (Chemotherapy) 01/2020 - 12/2019
1	Cardiac Resynchronization Therapy 09/2021
1	Continuity of Patient Care 03/2020
1	Glycemic Control 02/2013